113 related articles for article (PubMed ID: 25374008)
21. A novel chimeric Hepatitis B virus S/preS1 antigen produced in mammalian and plant cells elicits stronger humoral and cellular immune response than the standard vaccine-constituent, S protein.
Dobrica MO; Lazar C; Paruch L; Skomedal H; Steen H; Haugslien S; Tucureanu C; Caras I; Onu A; Ciulean S; Branzan A; Clarke JL; Stavaru C; Branza-Nichita N
Antiviral Res; 2017 Aug; 144():256-265. PubMed ID: 28666757
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity of high expression adenovirus-hepatitis B virus recombinant vaccines in dogs.
Chengalvala MV; Bhat BM; Bhat R; Lubeck MD; Mizutani S; Davis AR; Hung PP
J Gen Virol; 1994 Jan; 75 ( Pt 1)():125-31. PubMed ID: 8113721
[TBL] [Abstract][Full Text] [Related]
23. Immune response induced by a different combined immunization of HBsAg vaccine.
Wu T; Chen M; Ou SH; Cheng T; Zhang J; Xia NS
Intervirology; 2007; 50(5):336-40. PubMed ID: 17700028
[TBL] [Abstract][Full Text] [Related]
24. Oral immunization of mice with lily pollen expressing HBsAg.
Park HS; Park EH; Heo YJ; Heo Y
Biosci Biotechnol Biochem; 2013; 77(12):2492-4. PubMed ID: 24317059
[TBL] [Abstract][Full Text] [Related]
25. [The primary study on the anti-HBV effect of whole recombinant yeast].
Zeng Y; Cai DC; Peng ML; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2003 Dec; 11(12):728-30. PubMed ID: 14697133
[TBL] [Abstract][Full Text] [Related]
26. Chitosan-based nanoparticles for improving immunization against hepatitis B infection.
Prego C; Paolicelli P; Díaz B; Vicente S; Sánchez A; González-Fernández A; Alonso MJ
Vaccine; 2010 Mar; 28(14):2607-14. PubMed ID: 20096389
[TBL] [Abstract][Full Text] [Related]
27. Protective anti-hepatitis B virus responses in rhesus monkeys primed with a vectored measles virus and boosted with a single dose of hepatitis B surface antigen.
Reyes-del Valle J; Hodge G; McChesney MB; Cattaneo R
J Virol; 2009 Sep; 83(17):9013-7. PubMed ID: 19535451
[TBL] [Abstract][Full Text] [Related]
28. Host cell protein testing strategy for hepatitis B antigen in Hexavalent vaccine - Towards a general testing strategy for recombinant vaccines.
Toinon A; Fontaine C; Thion L; Gajewska B; Carpick B; Nougarede N; Uhlrich S
Biologicals; 2018 Jul; 54():1-7. PubMed ID: 29861269
[TBL] [Abstract][Full Text] [Related]
29. Use of SV40 to immunize against hepatitis B surface antigen: implications for the use of SV40 for gene transduction and its use as an immunizing agent.
Kondo R; Feitelson MA; Strayer DS
Gene Ther; 1998 May; 5(5):575-82. PubMed ID: 9797861
[TBL] [Abstract][Full Text] [Related]
30. Cationic polymers that enhance the performance of HbsAg DNA in vivo.
Bos GW; Kanellos T; Crommelin DJ; Hennink WE; Howard CR
Vaccine; 2004 Dec; 23(4):460-9. PubMed ID: 15530694
[TBL] [Abstract][Full Text] [Related]
31. Whole recombinant Hansenula polymorpha expressing hepatitis B virus surface antigen (yeast-HBsAg) induces potent HBsAg-specific Th1 and Th2 immune responses.
Bian G; Cheng Y; Wang Z; Hu Y; Zhang X; Wu M; Chen Z; Shi B; Sun S; Shen Y; Chen EJ; Yao X; Wen Y; Yuan Z
Vaccine; 2009 Dec; 28(1):187-94. PubMed ID: 19789093
[TBL] [Abstract][Full Text] [Related]
32. Hepatitis B virus core-preS2 particles expressed by recombinant vaccinia virus.
Nemecková S; Sroller V; Kunke D; Krystofová J; Kutinová L
Acta Virol; 1996; 40(5-6):273-9. PubMed ID: 9171455
[TBL] [Abstract][Full Text] [Related]
33. New vaccination strategies for low- and non-responders to hepatitis B vaccine.
Rendi-Wagner P; Wiedermann G; Stemberger H; Kollaritsch H
Wien Klin Wochenschr; 2002 Mar; 114(5-6):175-80. PubMed ID: 12238305
[TBL] [Abstract][Full Text] [Related]
34. Mechanical wounding of yeast-like conidium cells of Tremella fuciformis makes them susceptible to Agrobacterium-mediated transformation.
Shin DI; Park HS
Biosci Biotechnol Biochem; 2013; 77(10):2157-9. PubMed ID: 24096656
[TBL] [Abstract][Full Text] [Related]
35. Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine.
Shouval D; Roggendorf H; Roggendorf M
Med Microbiol Immunol; 2015 Feb; 204(1):57-68. PubMed ID: 25557605
[TBL] [Abstract][Full Text] [Related]
36. [Vaccination against hepatitis B in patients with chronic renal failure--twenty years follow-up].
Roznovský L; Tvrdík J; Kabieszová L; Petrousová L; Orságová I; Hozáková L; Lochman I; Kloudová A; Valkovský I; Letocha P; Schwarzová S; Hladík M; Zjevíková A
Vnitr Lek; 2011 Oct; 57(10):808-14. PubMed ID: 22097688
[TBL] [Abstract][Full Text] [Related]
37. Genetic immunisation against hepatitis B using whole bacteriophage lambda particles.
March JB; Clark JR; Jepson CD
Vaccine; 2004 Apr; 22(13-14):1666-71. PubMed ID: 15068849
[TBL] [Abstract][Full Text] [Related]
38. Immunological properties of recombinant HBsAg produced in yeast.
Hauser P; Voet P; Simoen E; Thomas HC; Pêtre J; De Wilde M; Stephenne J
Postgrad Med J; 1987; 63 Suppl 2():83-91. PubMed ID: 2446304
[TBL] [Abstract][Full Text] [Related]
39. [CpG oligodeoxyribonucleotide with HBsAg for vaccination in HBsAg-transgenic mice].
Sun YH; Zhu CM; Xie Y
Zhonghua Gan Zang Bing Za Zhi; 2005 Jan; 13(1):61-2. PubMed ID: 15670502
[No Abstract] [Full Text] [Related]
40. HIV-1 derived peptides fused to HBsAg affect its immunogenicity.
Gonzalez MC; Kostrzak A; Guetard D; Pniewski T; Sala M
Virus Res; 2009 Dec; 146(1-2):107-14. PubMed ID: 19766153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
